The 13th Annual

29 November 2017 | London Hilton on Park Lane

www.scripawards.com2017

Scrip Awards

Entry Guide

Sponsored by Headline Sponsor

Entry Deadline: 2 June 2017

www.scripawards.com

Who Can Enter

How To Enter

The Scrip Awards is open to any research-based pharmaceutical or biotech company operating anywhere around the world, as well as to some third party / partner companies that supply services to the pharmaceutical industry.

The Scrip Awards is free to enter.

1. Select the relevant category/ies for your business and review the entry criteria atscripawards.com

2. Prepare your entry off-line

3. Submit your entry by 2 June online via scripawards.com(you will receive an automated submission receipt)

Please refer to the category criteria as a guide.

The Final Entry Deadline is 2 June 2017.

Early Bird Deadline: Enter by 19 May 2017 to secure a 10% discount on your table.

To discuss event sponsorship opportunities please contact:

Christopher KeelingTel: +44 (20) 337 73183Mobile: +44 (0) 7917 647 859Email: christopher.keeling@informa.com

www.scripawards.com

• All entries must be written in English• Limit your entry to 1,500 words• All entries must be accompanied by a

250-word synopsis of the entry whichmay be used in Awards publicity material(this is in addition to the 1,500-wordentry)

• All entries must be submitted via ouronline entry system

• All entries must be based on activitiesundertaken from activities undertakensince 1 June 2016 to 31 May 2017

• Answer each question under a separateheading, as specified in the categorycriteria

• Do not provide any supporting

documentation – all information should be included within your 1,500-word entry

• Plan ahead to ensure it arrives in plentyof time so that, should it be incomplete,there will still be time to correct and re-submit it before the closing date.

• All entries will be treated as confidential,but Scrip reserves the right to publishpositive extracts from winning entries.

• All companies shortlisted as finalistswill be notified directly by Scrip by mid-September.

• The judging panel reserve the right tomove an entry into a different categoryif they feel it is better suited in thiscategory.

For this special Award, candidates must be nominated by a third party. The nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

All nominations must include:• The name of the nominee• The job title of the nominee (if applicable)• The company name (if applicable)• Your contact details• The contact details of the nominee• A précis of up to 750 words of why you

think your nominee is worthy of receivingthe Lifetime Achievement Award.

Entry Guidelines

Multiple Entries

Lifetime Achievement Awards Nominations

Companies may enter more than one category, provided that each entry has been specifically written to address the relevant criteria and is accompanied by a separate 250-word synopsis.

www.scripawards.com

Best Company in an Emerging Market

Scrip’s Best Company in an Emerging Market Award seeks to reward the growing R&D-based pharmaceutical industry founded in areas beyond its traditional geographic borders of North America, Western Europe and Japan.

This Award is open to any research-based pharmaceutical or biotechnology company that has its headquarters in an emerging market.

The judges will be looking for excellent performance across a range of business activities between June 1, 2016 and May 31, 2017. This could mean anything from growing sales and profits to launching new products, or signing a transformative new deal.

Companies eligible for this Award are those based in emerging markets in Asia, central and eastern Europe, central and south America, the Middle East and Africa.

To enter this category, please answer the following:• Please give the name of the entering company and country where it is headquartered

• What has been this company’s most significant achievement during the year?

• Give details of what this company has achieved in terms of:- Growth in sales and profits- Signing important new deals- Introducing new products onto the market- Producing a promising new drug pipeline- Operational improvements, particularly after restructuring, or changing the focus of the

business.

Scrip Awards 2017 Categories

www.scripawards.com

Best Technological Development in Clinical Trials – Sponsor-focused

The Scrip Awards for Best Technological Development in Clinical Trials recognize the promising and disruptive role that digital health technology now plays in clinical drug development. The award for Best Technological Development in Clinical Trials is split into two this year, with categories rewarding advances that are focused on helping sponsors, and those designed to ease the experience of clinical trial participants.

This Sponsor-focused Award recognizes the vital importance of using the most sophisticated platforms to catalyze and optimize data gathered during clinical trials. Advances in software and applications have a pivotal role to play at all stages of the trial process, assisting sponsors in effective management of study logistics, monitoring, risk mitigation and timely data collection and analysis. The judges will be looking for the product or suite of products that help study teams better manage and oversee clinical trial activities.

All technologies launched or significantly updated between June 1, 2016 and May 31, 2017 are eligible to enter.

Companies wishing to enter must have played a role in the development of the nominated technology, and all parties to any joint development agreements should be disclosed in the application.

To enter this category, please provide the following:• The name of all companies involved in the product development, including an outline of

their role(s)

• Specify the date and market of the technology’s first launch, if applicable

• Outline the key features and benefits of the technology, and how they support the clinical trial process

• What problems does this product solve and what is novel about it?

• What is the single most significant benefit of the entrant’s technology to users?

• Give an estimate of how much the technology could save a sponsor (in US$ or time) on a typical protocol compared with existing solutions

• If possible, please provide a link to a product demo (product webpage, YouTube video, etc.).

www.scripawards.com

Best Technological Development in Clinical Trials – Patient-focused

The Scrip Awards for Best Technological Development in Clinical Trials recognize the promising and disruptive role that digital health technology now plays in clinical drug development. The award for Best Technological Development in Clinical Trials is split into two this year, with categories rewarding advances that are focused on helping sponsors, and those designed to ease the experience of clinical trial participants.

This Patient-focused Award recognizes the development of smartphone apps, mobile health devices, and a host of other products that are revolutionizing the way patients participate in clinical trials. The judges will be looking for the product that represents the best advance in improving patient data collection and/or the patient experience in clinical trials. Those considered may include electronic patient diaries, mobile health devices or any other digital tools that support, encourage or aid the patient’s participation in the clinical trial.

All technologies launched or significantly updated between June 1, 2016 and May31, 2017 are eligible to enter.

Companies wishing to enter must have played a role in the development of the nominated technology, and all parties to any joint development agreements should be disclosed in the application.

To enter this category, please provide the following:• The name of all companies involved in the product development, including an outline of

their role(s)

• Specify the date and market of the technology’s first launch, if applicable

• Outline the key features and benefits of the technology, and how they support the patient’s clinical trial journey

• What problems does this product solve and what is novel about it?

• What is the single most significant benefit of the entrant’s technology to users?

• Give an estimate of how much the technology could save a sponsor (in US$ or time) on a typical protocol compared with existing solutions

• If possible, please provide a link to a product demo (product webpage, YouTube video, etc.).

www.scripawards.com

Community Partnership of the Year Award

This Award, inaugurated last year, is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organization.

The judges will be looking for effective partnership activity that took place between June 1, 2016 and May 31, 2017 to the benefit of humankind. Types of partnerships could include, for example, patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.

To enter this category, please answer the following:• Please give the name of the entering company and the name of the partnership

• Please outline the nature of the partnership being entered

• What were the aims of the partnership?

• What were the benefits of the partnership and how were they measured?

• What lessons were learned from the partnership and how might it be improved in future?

www.scripawards.com

Best Partnership Alliance – Sponsored by INC Research

Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs.

The judges will be focusing on deals that require strong strategic input from both partners, involving business development, joint marketing/promotion or joint R&D. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure.

Partnerships must have been announced, or have achieved a significant milestone, between June 1, 2016 and May 31, 2017 and entrants should be able to show some sustained benefits from the deal. NB: Deals between majority or wholly owned subsidiaries and their parent companies are not eligible for this Award.

To enter this category, please answer the following:• Please give the name of company/organizations involved

• Please outline the structure of the partnership, detailing the parties involved, what it covers and the responsibilities on both sides

• Does its structure represent an innovative business model, and if so how? How does it demonstrate that either party was the “partner of choice”?

• Please summarize the strategic potential of the deal, and if applicable the milestone reached

• Please explain how the deal is mutually beneficial to both parties

• What aspect of the deal makes it unique or particularly special?

• How does the collaboration hope to meet any unmet medical need?

IMPORTANT NOTEWould your deal fit better into the Licensing Deal of the Year category? Please check before you enter.

www.scripawards.com

Financing Deal of the Year

This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public-private partnership deals to venture fundraising and public offerings, but should be earmarked for use in drug discovery and/or development.

In making their decision, the judges will scrutinize entrants on their fundraising strategy, amount raised, the structure of the deal, and on how the money will be used. This Award is open only to companies actually raising the funds (i.e., not bankers or agents). To be eligible, all financing must have been announced between June 1, 2016 and May 31, 2017.

To enter this category, please answer the following questions:• Please outline the form of the financing, how much money was raised (including how

this compares with the company’s capital base), and how close was this to meeting your fundraising objectives?

• Please explain how this source of financing was best suited to your purposes

• Please describe how this fundraising was particularly creative. Has this set a precedent that has since been repeated?

• Did the funding succeed in other ways, such as bringing on board a new kind of investor?

• How will the money be used?

• Please give evidence of early value creation from the deal.

www.scripawards.com

QuintilesIMS’ Clinical Advance of the Year Award

This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

Unlike the Best New Drug Award, the product involved need not yet be approved, but as with that award the judges will be looking for innovation, clear proof of benefit and potential commercial reward.

To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between June 1, 2016 and May 31, 2017.

Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.

To enter this category, please answer the following questions:• Please give full details of the study, i.e., its name (protocol ID, trial identifier), Phase,

disease type and patients segment studied, sponsors, and the primary drug tested

• Please summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints

• How does the drug work in the setting tested?

• How do these findings represent a potential leap forward in therapy, or fulfil an unmet medical need?

• What could be the potential market size of this breakthrough?

www.scripawards.com

Licensing Deal of the Year – Sponsored by Worldwide Clinical Trials

Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing. (NB It does not include more involved partnerships between companies to explore particular therapeutic strategies (see criteria for the Best Partnership Alliance Award).)

In choosing the winner of Scrip’s Licensing Deal of the Year Award, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to the benefits they give to both sides. To qualify, licensing deals must have been closed between June 1, 2016 and May 31, 2017.

To enter this category, please answer the following:• Please outline the structure of the deal, giving the names of the parties involved, the drug

candidate(s) concerned, and what rights it covers

• What is the monetary value of the deal in up-front and milestone payments?

• What is the geographic spread of the deal? Does it allow any party to enter new markets?

• What is the strategic value of the licensed product to the licensee’s business?

• Please explain how the licensed product was the best possible candidate to complement the rest of the licensee’s pipeline or particular disease franchise.

IMPORTANT NOTEWould your entry fit better in the Best Partnership Alliance category? Please consider before you enter.

www.scripawards.com

Executive of the Year – Sponsored by Lachman Consultants

Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies. This year’s winner will be the executive who has exhibited exemplary leadership throughout the year from June 1, 2016 to May 31, 2017.

This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities.

To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.

To enter this category, please answer the following:• Please give the name, company and position of the entrant, and the date of taking up this

post

• What have been the entrant’s greatest achievements during the qualifying year? What has been the direct consequence of these on company performance?

• How have these achievements strengthened the candidate’s influence within the industry? Please give examples

• What are the entrant’s greatest strengths as a leader? Please show how these have had a bearing on their achievements this year

• What specific previous accomplishments did the entrant have that made them perfectly fitted to achieving this success? For example, previous scientific or management experience.

www.scripawards.com

Best Contract Research Organization – Full-Service Providers

The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.

This year the award has been split into two categories to separate the full-service providers from those smaller CROs that provide niche services to their clients.

Today, the role of the CRO has gone beyond the traditional model of service-level agreements to offer bespoke clinical trial strategies and CROs are increasingly engaged in risk-sharing partnerships or acting as a single-source developer while also remaining committed to core strengths.

This Award for those companies who provide the full range of services to their clients will be judged on the quality of services and relationships they have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal.

To qualify, candidates must draw on their achievements in the year between June 1, 2016 and May 31, 2017.

To enter this category, please answer the following:• What particular capabilities and strengths does the CRO offer?

• How has this firm delivered results that exceed sponsor expectations?

• What innovations in patient recruitment strategy has the CRO brought to its partner?

• How has it improved its performance, for example, in its quality of data, timelines and transparency?

• What steps is the company taking towards streamlining data collection and reporting?

www.scripawards.com

Best Contract Research Organization – Niche Providers

The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.

This year the award has been split into two categories to separate the full-service providers from those smaller CROs that provide niche services to their clients.

This Award for those companies who provide niche services to their clients will be judged on the quality of services and relationships they have built with their clients.

To qualify, candidates must draw on their achievements in the year between June 1, 2016 and May 31, 2017.

To enter this category, please answer the following:• What particular capabilities and strengths does the CRO offer?

• How has this firm delivered results that exceed sponsor expectations?

• What innovations has the CRO brought to its partner?

• How has it improved its performance, for example, in its quality of data, timelines and transparency?

• What steps is the company taking towards streamlining data collection and reporting?

www.scripawards.com

WuXi AppTec’s Biotech Company of the Year Award

The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This award honors outstanding achievement by biotech companies over the qualifying 12 months.

The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between June 1, 2016 and May 31, 2017. This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

To enter this category, please answer the following:• Name of entering company

• What has been the company’s most significant achievement during the year?

• Give details of what the firm has accomplished over the year in terms of: - Bringing new products closer to their first markets - Raising funds - Signing significant licensing or partnership deals - Showing strong management not afraid of making hard decisions - Using proprietary science or technologies to address an unmet medical need - Successfully transforming the business from an early stage to a more mature company.

www.scripawards.com

Business Development Team of the Year

Scrip’s Business Development Team of the Year Award will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.

This Award will go to a team that is truly much more than the sum of its parts. The judges will be looking for strong performance across a number of criteria, such as achievement of short and long-term goals, and good communication of a shared vision.

To enter this category, please answer the following:• Please give details of the company(ies), the particular team being entered and its core

function

• Please describe the team’s goals and vision, and how these are communicated

• What was the greatest achievement of the team during the year between June 1, 2016 and May 31, 2017?

• Please describe how all parts of the team were fully aligned to achieve this, including how supporting functions, such as HR, finance and IT, were integrated into the team

• Rate the team, giving justification, according to the following criteria: - Achieving short-term and long-term goals - Managing resources - Providing a platform for professional development and teamwork - How does the team embody a management model that others should follow?

www.scripawards.com

HUYA Bioscience International’s Best New Drug Award

The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.

In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.

All recently launched new active substances, including small-molecules, biologicals or vaccines, are eligible to enter as long as they were first licensed in any market between June 1, 2016 and May 31, 2017. Generic and biosimilar products are not eligible for this award.

Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.

To enter this category, please answer the following:• Please give the trade and generic name of the entrant, the therapeutic indication for which

it is being considered, and the company(ies) involved in its development (if more than onecompany, please detail the relationship between the parties)

• What was the date and market of the candidate’s first approval and launch?

• Please explain the mechanism of action of the candidate. How does this represent a stepforward in treatment in this therapeutic area?

• Please outline the evidence for the product’s clinical activity. How does its activity translateinto a meaningful therapeutic benefit for patients, and how is this benefit over and abovethat provided by other treatments in this area?

• How does the entrant address an unmet medical need?

• What is the potential market size of the candidate?

www.scripawards.com

PPD’s Pharma Company of the Year Award

The Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies over the qualifying 12 months, June 1, 2016 and May 31, 2017. This special award is chosen by Scrip’s senior editorial team, based on a variety of key metrics:

• Financial performance in 2016 compared with the previous year

• Strategic advances, looking at its most significant achievements over the year

• Progress in the emerging markets

• New product launches including line-extensions and formulations

• Advances in the drug pipeline, including major clinical trial reports.

www.scripawards.com

Scrip’s Lifetime Achievement Award

The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career.

This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry. Nominees may be retired or semi-retired but will still be active in the industry in some capacity. For this special Award, candidates must be nominated by a third party.

The nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

All nominations must include:• The name of the nominee

• The job title of the nominee (if applicable)

• The company name (if applicable)

• Your contact details

• The contact details of the nominee

• A précis of up to 750 words of why you think your nominee is worthy of receiving the Lifetime Achievement Award.

www.scripawards.com

The Scrip Awards will culminate in a gala black-tie dinner and awardsceremony on Wednesday 29 November at the London Hilton on Park Lane. For security purposes, attendance at the event is by ticket only and guests are required to provide some personal details beforehand. All shortlisted companies and individuals are required to attend the Awards ceremony.

To discuss event sponsorship opportunities please contact:

Christopher KeelingTel: +44 (20) 337 73183Mobile: +44 (0) 7917 647 859Email: christopher.keeling@informa.com Or visit www.scripawards.com

• Read the entry details and judging criteria carefully for each category before starting your submission

• Write your entry specifically for the category in question, check the nomination is in the correct category and would not stand a better chance of winning in a different category

• Do not exceed the word limits. Entries should be 1,500 words, executive summaries 250 words, and there should be no supporting material

• Ensure the activities included were undertaken between the date parameters, 3 June 2016 to 31 May 2017

• Ensure each entry meets the specific criteria for its category

• Ensure you have answered each entry question under a separate heading in your submission

• Plan ahead to ensure it arrives in plenty of time so that, should it be incomplete, there will still be time to correct and re-submit it before the closing date of 2 June 2017.

How Are The Scrip Awards Presented?

Useful Tips For A Winning Entry

www.scripawards.com

Dr Laura BrownDirector, LB Training and Development

Brown is an independent pharmaceutical project management, QA and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy. She has more than 20 years of experience of managing clinical development projects, and training in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and LB Training and Development. She is also co-author of several books including, Project Management for the Pharmaceutical Industry.

Clive DixCEO, C4X Discovery

Dix is one of the UK’s leading pharma and biotech entrepreneurs. He has more than 25 years’ experience life sciences, with over 20 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology.

Dix is currently CEO of C4X Discovery plc and Chairman of Centauri Therapeutics Ltd and Touchlight Ltd, and is also a non-executive director of the Medicines Discovery Catapult. Dix was formerly co-founder and chief executive of Convergence Pharmaceuticals Ltd., a pain-specialist pharmaceuticals company acquired by Biogen Idec in 2015. Previously he had been a founder and CEO of PowderMed Ltd, and chair of Auralis Ltd. Before that Dix was held R&D roles at PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003, and GlaxoWellcome.

Scrip Awards 2017 Judging Panel

www.scripawards.com

Laurie A. HalloranPresident, Halloran Consulting

Halloran is the president of Halloran Consulting Group, founded in 1998. With over 30 years in life science management, she has become recognized as an industry expert through her group’s work in bringing world-class expertise to plan and build early-stage life science companies, and to transform and restore large life science companies to nimble and high quality organizations.

In 2017 Halloran was awarded Enterprising Woman of the Year and in 2015, Halloran was honored by the Boston Business Journal as a Woman of Influence. The company has received a ranking in the INC 500 fastest growing companies for the past three years. In 2010, Halloran was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice and in 2009, she was awarded clinical researcher of the year by ACRP.

Dennis GillingsCo-founder and former Executive Chairman, Quintiles

Gillings is recognised as a visionary pioneer in the contract research organisation industry. He is co-founder and former executive chairman of Quintiles Transnational, the world’s largest biopharmaceutical services company. Gillings retired as executive chairman in 2015, although he remains on the board of the Fortune 500 company.

In 2014, Gillings was appointed World Dementia envoy by former UK Prime Minister David Cameron. In this capacity he chaired the World Dementia Council, an organization that seeks to stimulate innovation to treat cognitive decline.

As envoy, he worked with governments to provide a global leadership role in addressing the economic, regulatory and social barriers to innovation in dementia prevention, treatment, and care. Gillings has seen firsthand the devastating effects of dementia and lack of effective treatment, as his mother lived with the condition for 18 years until her death in 2013.

Prior to founding Quintiles, Gillings was a professor of biostatistics at the University of North Carolina at Chapel Hill for more than 15 years. Among the many honours he has received, Gillings was awarded a CBE in 2004 for services to the pharmaceutical industry.

www.scripawards.com

Professor Trevor M Jones CBE Chair, Simbec-Orion Group, and Director, Arix Bioscience

Jones is chair of Simbec-Orion Group and Director Arix Bioscience plc. He was formerly R&D director of The Wellcome Foundation, a director of Allergan Inc. and director general of the Association of the British Pharmaceutical Industry (ABPI). He is a visiting professor at King’s College, London 

Brian HargreavesIndependent Adviser

Hargreaves is an independent adviser for private equity. His career in healthcare spans academia, pharma, venture capital and private equity.

Following his early career as a lecturer in pharmacy at Manchester University, he had a series of commercial and international marketing roles with Smith Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra Hässle which included the commercialisation of the blockbuster Nexium. In 1997, he moved to 3i plc in the innovative growth period of biotech venture capital. More recently he originated several significant growth capital deals and buyouts.

Hargreaves currently advises selected private equity firms and spends a proportion of his time in the charity sector.

www.scripawards.com

Dr Alison MessomChair, Institute of Clinical Research, and Director, ALM Consultancy

Since 2012, Messom has been chairman of the Institute of Clinical Research; the oldest independent membership-led professional body for global clinical researchers. With a background in molecular genetics, Messom has almost 20 years’ industry experience working both within pharmaceutical companies and clinical research organisations.

Messom has detailed experience of directing global clinical trials and has worked in a wide variety of leadership roles, within pharma companies and CROs not only for project and monitoring teams, but also data management, outsourcing, informatics and translational medicine departments. Most recently she has provided consultancy support to an academic group working on a translational medicine project and operational consultancy to a mid-sized pharma company working in Phase III and IV.

Viren MehtaFounder, Mehta Partners

Mehta founded and is managing member of Mehta Partners, LLC. His analytical insights on global healthcare have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California and UCLA, he has worked with senior biopharma leaders and investment managers for over 30 years.

Mehta’s career began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly, now known as Mehta Partners.

Gather Health is Mehta’s new initiative to empower patients while enhancing physician productivity. Gather Health brings together healthcare providers and patients’ social networks, enabling patients to get real-time and active resources and motivation to improve outcomes.

www.scripawards.com

Peter PittsPresident, Center for Medicine in the Public Interest

Pitts is president of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Pitts was the FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised the FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee consultant to the FDA’s Risk Communications Advisory Committee.

His specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, DTC/ItP, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, and nutritional labeling.

Phornvit PhacharintanakulChair, Strategic Business Partners

Phacharintanakul is chair of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chair of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.

www.scripawards.com

Raymond F. Schinazi

Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and co-Director of the HIV Cure Scientific Working Group for the NIH-sponsored Emory University Center for AIDS Research. Schinazi has authored over 500 peer-reviewed papers and seven books and holds over 100 issued US patents, which have resulted in 15 NDAs.

A world leader in nucleoside chemistry, Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs stavudine, lamivudine, emtricitabine, telbivudine, and most recently sofosbuvir. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented.

After 35 years of service, Schinazi retired from the Department of Veterans Affairs with his latest position as senior research career scientist. Schinazi was appointed to the Global Virus Network executive committee in 2016.

Andy SmithSenior Principal, Pricing & Market Access, Commercialisation and Outcomes, ICON PLC

Smith began his career as a scientist in the research and development division of ICI and then SmithKline Beecham. After completing his PhD in Molecular Biology at the University of Nottingham and with Glaxo, after then an MBA, Smith switched to a commercial role at SB Pharmaceuticals and was appointed global brand manager for Bactroban and new products in the Anti-Infectives Global Marketing Group. In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for three life science specific funds – 3i Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and AXA Framlington Biotech Fund. Smith was awarded the Techmark technology fund manager of the year for 2007.

After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years. Smith returned to specialist fund management in 2012 to manage the Magna Biopharma Income Fund.

In 2017 Andy moved to the Pricing & Market Access group at ICON in London where he advises big pharma and smaller life science companies on the valuation and commercialisation of their products.

www.scripawards.com

Dr Brian TempestChair, Hale & Tempest Co Ltd, and Editor, Journal of Generic Medicines

Tempest has worked in the pharmaceutical industry for the last 46 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 he held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories. Previously, Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa. Today, as Chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net-worth individuals on their strategy in Asia. Tempest is a non-executive director of SRL Diagnostics, Fortis Healthcare, Touch Digital Media, Religare Capital Markets and Glenmark Pharmaceuticals. Currently he is Editor of the Journal of Generic Medicines and a non-executive director of the United Nations Medicines Patent Pool.

Robert SpiegelFounder, Spiegel Consulting

Spiegel is the founder of Spiegel Consulting, an independent advisory firm to pharma and biotechnology companies. He retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research. Spiegel is a fellow of the American College of Physicians and has received numerous awards and fellowships.

He serves as an advisor to Warburg Pincus and the Israeli Biotech Fund and on the boards of numerous biotechnology companies and non-profit organizations. He is an assistant professor Weill Cornell Medical School and associate fellow in the University of Pennsylvania Center for Bioethics.

www.scripawards.com

Robert ThongIndependent Consultant and Writer

Thong consults on business strategy and collaborations in the bioscience sector, and writes a regular blog on these topics, SciTechStrategy. Thong’s full-length book, Biopharma R&D Partnerships: From David & Goliath to Networked R&D, was published in January 2016, derived from the practical experiences of over forty different organisations. He has previously been co-head of the Cap Gemini Life Sciences Group, managing director of Datamonitor’s healthcare division, a non-executive board member of the listed US mid-sized pharmaceutical company Alpharma, and a co-founder of two specialist consultancies focusing respectively on mid-sized biopharma companies and change management for scientific organisations.

Sir Gregory WinterMaster, Trinity College Cambridge

Winter is the Master of Trinity College, Cambridge and a Fellow of the Royal Society and until recently a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist, inventor and entrepreneur and best known for his research and inventions relating to therapeutic antibodies made at the LMB.

He has founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GlaxoSmithKline) and Bicycle Therapeutics in 2009.

www.scripawards.com

The Scrip Awards prides itself on its Judging Panel, comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

The judges separately consider entries from those categories that are relevant to their particular areas of specialist knowledge, expertise and experience, ensuring a considered response to every individual submission. Each category is reviewed by at least three judges.

The judges mark each entry against the published criteria for its category, and the scores are marked out of five for each category answer. These are then collated by the Scrip Awards team to determine which entries are included in the shortlist, and the ultimate winner.

The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges’ decision is final and neither the organisers nor the Judging Panel will enter into any correspondence about the results. Judging will take place throughout July, and the shortlist will be announced in early September. Details of the winners are strictly embargoed until the night but further details of all of the shortlisted entries will be published in Scrip in the weeks leading up to the ceremony on Wednesday 29 November at the London Hilton on Park Lane.

How Do The Judges Select The Awards Winners?

Informa, organizer of the Scrip Awards, recognizes and respects the sensitive nature of the information submitted in the entries. We ensure that this recognition is shared by our Judging Panel and therefore require each judge to sign a confidentiality agreement before they are appointed. Entries are not disclosed or discussed outside the judging process. The Judging Panel for each Award is selected to avoid any conflict of interest. Once an entry is shortlisted, extracts from the entry summary only will be sourced for inclusion in the Awards ceremony and any subsequent editorial coverage. Please ensure your entry summary contains no confidential or sensitive information.

Confidentiality